

| | |
|-------------------------|----------------------------------|
| Reference: | FOI.18631.25 |
| Subject: | New Patients in Gastroenterology |
| Date of Request: | 17 October 2025 |

Requested:

1. How many new patients were treated by the Trust's Gastroenterology Department in the latest 3 month period of July, August and September (or the latest 3 months available) with the treatments I have provided below?

a. If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st July 2025, they are not classed as a new patient for the purposes of this question.

| | Total Gastroenterology Department | Crohn's Disease | Ulcerative Colitis |
|------------------------------|-----------------------------------|-----------------|--------------------|
| Adalimumab [Humira] | | | |
| Adalimumab [All Biosimilar] | | | |
| Etrasimod | | | |
| Filgotinib | | | |
| Golimumab | | | |
| Infliximab [Remicade] | | | |
| Infliximab [All Biosimilar] | | | |
| Mirikizumab | | | |
| Ozanimod | | | |
| Risankizumab | | | |
| Tofacitinib | | | |
| Upadacitinib | | | |
| Ustekinumab [Stelara] | | | |
| Ustekinumab [All Biosimilar] | | | |
| Vedolizumab | | | |

Clarification

If a patient received any of the drugs before the 1st June 2025, they can be classed as a new patient for the purposes of this question.

Response:

Hywel Dda University Health Board (UHB) has been unable to fulfil the provided definition of a 'new patient', but instead has defined a 'new patient' as those 'new to advanced therapies' utilising the descriptors provided below:

- A patient is considered new to advanced therapies if they started any advanced therapy on or after the 1 July 2025.
- A patient who is already on an advanced therapy before 1 July 2025 and subsequently switched to another advanced therapy is not counted as a new patient.

A new patient was considered under Gastroenterology care if any of the following applied:

- Pharmacy Cost Centre
 - The latest recorded pharmacy cost centre for the patient is Gastroenterology.
- Clinic Attendance
 - The patient has coding data indicating attendance at a Gastroenterology clinic.
- Treatment Licensing
 - The patient is receiving a treatment that is licensed only for a Gastroenterology condition.
- Manual Record Check
 - If none of the above data points are available, a manually check is required to confirm if the patient is under Gastroenterology care. This will also include some patients being treated by the Paediatric Gastroenterologists.

The UHB is unable to provide you with some of the patient numbers requested due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller

Therefore, the UHB provides within the table below, the number of new Gastroenterology patients, treated with the listed medications, split by medical condition, during the period 1 July to 30 September 2025.

| Medication | Total Gastroenterology Department | Crohns Disease | Ulcerative Colitis | Undifferentiated Inflammatory Bowel Disease (IBD) |
|-----------------------------|-----------------------------------|----------------|--------------------|---|
| Adalimumab [Humira] | 0 | 0 | 0 | 0 |
| Adalimumab [All Biosimilar] | 11 | * | * | 0 |
| Etrasimod | 0 | | 0 | 0 |
| Filgotinib | * | | * | 0 |
| Golimumab | 0 | 0 | 0 | 0 |
| Infliximab [Remicade] | 0 | 0 | 0 | 0 |
| Infliximab [All Biosimilar] | 13 | 5 | 8 | 0 |
| Mirikizumab | 0 | 0 | 0 | 0 |

| | | | | |
|---------------------------------|----|---|---|---|
| Ozanimod | 0 | | 0 | 0 |
| Risankizumab | * | * | * | * |
| Tofacitinib | 0 | | 0 | 0 |
| Upadacitinib | * | 0 | * | 0 |
| Ustekinumab [Stelara] | 0 | 0 | 0 | 0 |
| Ustekinumab [All Biosimilar] | * | * | * | 0 |
| Vedolizumab | 10 | * | 6 | * |